Vontobel Asset Management Has Lifted Medtronic Plc (MDT) Holding By $16.49 Million; Five Prime Therapeutics (FPRX) Has 1.04 Sentiment

February 20, 2018 - By Clifton Ray

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $623.76 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

Vontobel Asset Management Inc increased Medtronic Plc (MDT) stake by 8.46% reported in 2017Q3 SEC filing. Vontobel Asset Management Inc acquired 206,157 shares as Medtronic Plc (MDT)’s stock rose 5.51%. The Vontobel Asset Management Inc holds 2.64 million shares with $212.17 million value, up from 2.44 million last quarter. Medtronic Plc now has $112.76 billion valuation. The stock increased 0.45% or $0.37 during the last trading session, reaching $83.31. About 6.86M shares traded or 28.05% up from the average. Medtronic plc (NYSE:MDT) has risen 4.04% since February 20, 2017 and is uptrending. It has underperformed by 12.66% the S&P500.

Vontobel Asset Management Inc decreased Philip Morris Intl Inc (NYSE:PM) stake by 55,653 shares to 4.37M valued at $475.60 million in 2017Q3. It also reduced Alibaba Group Hldg Ltd (NYSE:BABA) stake by 1.26M shares and now owns 9.26M shares. Wells Fargo Co New (NYSE:WFC) was reduced too.

Investors sentiment increased to 1.12 in 2017 Q3. Its up 0.22, from 0.9 in 2017Q2. It is positive, as 73 investors sold MDT shares while 392 reduced holdings. 109 funds opened positions while 414 raised stakes. 1.07 billion shares or 1.07% more from 1.06 billion shares in 2017Q2 were reported. Brown Advisory Securities Ltd Liability Corp has 0.06% invested in Medtronic plc (NYSE:MDT). Wheatland reported 0.98% stake. Advsr Cap Limited Liability Co, a New Jersey-based fund reported 119,508 shares. Brighton Jones Limited Liability Corporation stated it has 3,086 shares or 0.03% of all its holdings. Logan Management Inc stated it has 3,264 shares or 0.02% of all its holdings. First Washington invested 1.72% of its portfolio in Medtronic plc (NYSE:MDT). Moreover, Folger Nolan Fleming Douglas Cap Inc has 0.05% invested in Medtronic plc (NYSE:MDT) for 4,266 shares. Marshwinds Advisory holds 16,671 shares or 0.6% of its portfolio. Moreover, Citigroup has 0.09% invested in Medtronic plc (NYSE:MDT). Buckhead Mngmt Ltd Liability Corp invested in 3,545 shares. Artisan Partners Partnership has invested 3.43% in Medtronic plc (NYSE:MDT). Endurance Wealth Mgmt stated it has 0.02% of its portfolio in Medtronic plc (NYSE:MDT). Atlanta Capital Management Company L L C invested 0.03% in Medtronic plc (NYSE:MDT). Chevy Chase Tru invested in 0.44% or 1.25M shares. Martin Inc Tn invested 0.57% in Medtronic plc (NYSE:MDT).

Among 28 analysts covering Medtronic (NYSE:MDT), 18 have Buy rating, 0 Sell and 10 Hold. Therefore 64% are positive. Medtronic had 79 analyst reports since August 10, 2015 according to SRatingsIntel. IBC maintained the stock with “Buy” rating in Monday, May 29 report. The firm earned “Hold” rating on Wednesday, August 23 by Northland Capital. Cowen & Co maintained it with “Buy” rating and $95.0 target in Tuesday, August 22 report. On Thursday, July 6 the stock rating was maintained by William Blair with “Outperform”. The stock of Medtronic plc (NYSE:MDT) earned “Outperform” rating by BMO Capital Markets on Tuesday, October 10. The stock of Medtronic plc (NYSE:MDT) earned “Buy” rating by SunTrust on Friday, November 17. The stock of Medtronic plc (NYSE:MDT) earned “Outperform” rating by Credit Suisse on Monday, August 10. On Tuesday, August 22 the stock rating was maintained by Oppenheimer with “Buy”. UBS maintained it with “Buy” rating and $94 target in Friday, February 17 report. On Wednesday, April 19 the stock rating was maintained by RBC Capital Markets with “Buy”.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on February, 22. They expect $-1.29 EPS, down 76.71% or $0.56 from last year’s $-0.73 per share. After $-1.54 actual EPS reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -16.23% EPS growth.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $148,468 activity.

Eventide Asset Management Llc holds 1.39% of its portfolio in Five Prime Therapeutics, Inc. for 601,000 shares. Healthcor Management L.P. owns 1.01 million shares or 1.39% of their US portfolio. Moreover, Bb Biotech Ag has 0.88% invested in the company for 777,500 shares. The New York-based Awm Investment Company Inc. has invested 0.71% in the stock. Granite Point Capital Management L.P., a Massachusetts-based fund reported 50,000 shares.

The stock decreased 2.19% or $0.41 during the last trading session, reaching $18.34. About 324,107 shares traded. Five Prime Therapeutics, Inc. (FPRX) has declined 30.56% since February 20, 2017 and is downtrending. It has underperformed by 47.26% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>